{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:11:00Z","timestamp":1779253860422,"version":"3.51.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the current capacity for breast cancer diagnosis and treatment in county-level medical institutions in Sichuan Province, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional observational study was conducted between December 2023 and January 2024.\u00a0A retrospective questionnaire was administered to 124 county-level medical institutions in Sichuan Province that reported providing breast cancer services. Survey domains included hospital grade and ownership, oncology accreditation, breast specialty section\/group setup and staffing, breast cancer diagnostic and therapeutic techniques, AJCC TNM staging documentation rates, and access to antineoplastic and palliative care agents. Data were analyzed using descriptive statistics with SPSS version 22.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 124 institutions surveyed, six were excluded because they had not treated any breast cancer patients in 2023, leaving 118 for analysis. Tertiary hospitals accounted for 78.81% and public hospitals for 94.07%. 75.42% of institutions held qualifications for special outpatient services, while 57.63% possessed both recognition for special antineoplastic drugs and prescribing authority. An independent breast specialty section\/group existed in 57.63% of institutions, but only 16.95% were equipped with a comprehensive multidisciplinary team. Simultaneous availability of breast ultrasound, CT, MRI, and mammography was reported by 33.90%; PET-CT and bone scintigraphy were available in 7.63% and 11.02%, respectively. Independent pathology departments existed in 71.19% of cases. Breast cancer surgery was performed in 86.44% of institutions and breast-conserving surgery in 44.07%; The radiotherapy provision rate was 38.98%. The AJCC TNM staging rate was 77.12%. Complete availability rates for conventional chemotherapy agents, anti-HER2 targeted therapies, endocrine agents, and CDK4\/6 inhibitors were 33.90%, 22.88%, 47.46%, and 10.17%, respectively. Strong opioids for pain control and several key antiemetics showed variable accessibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Breast cancer diagnostic and treatment capacity in county-level hospitals in Sichuan Province remains limited, reflecting common challenges in low- and middle-income countries (LMICs). Key deficiencies include underdeveloped dedicated breast oncology units, insufficient specialized personnel, restricted access to advanced imaging and innovative therapies (especially CDK4\/6 inhibitors and anti-HER2 agents), and suboptimal availability of strong opioids and novel antiemetics for palliative care. Targeted policy interventions are needed to strengthen infrastructure, workforce, and drug accessibility at the county level. These findings provide valuable insights for improving breast cancer care in other resource-constrained settings globally.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1847827","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:47:27Z","timestamp":1779252447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status of breast cancer diagnosis and treatment capacity in county-level medical institutions in Sichuan Province, China: a cross-sectional study"],"prefix":"10.3389","volume":"16","author":[{"given":"Le","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Anyue County People\u2019s Hospital","place":["Ziyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Dujiangyan People\u2019s Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Colorectal, Gastrointestinal, and Burn Surgery, The Second People\u2019s Hospital of Neijiang","place":["Neijiang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Anyue County People\u2019s Hospital","place":["Ziyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Anyue County People\u2019s Hospital","place":["Ziyang, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20241127-00538","article-title":"Epidemiological characteristics of female breast cancer in China and worldwide","volume":"47","author":"Xu","year":"2025","journal-title":"Chin J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13958","article-title":"Incidence, mortality, survival, and disease burden of breast cancer in China compared to other developed countries","volume":"19","author":"Tao","year":"2023","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e70032","DOI":"10.1002\/cai2.70032","article-title":"Guidelines for the diagnosis and treatment of advanced breast cancer in China (2024 edition)","volume":"4","year":"2025","journal-title":"Cancer Innovation"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e70005","DOI":"10.1002\/cai2.70005","article-title":"Guideline for the management pathway and quality control of breast cancer prevention and treatment in China's counties","volume":"4","year":"2025","journal-title":"Cancer Innovation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Center"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(18)30127-x","article-title":"Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries","volume":"6","author":"Zeng","year":"2018","journal-title":"Lancet Global Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(24)00003-3","article-title":"The effect of health-care privatisation on the quality of care","volume":"9","author":"Goodair","year":"2024","journal-title":"Lancet Public Health"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population\u2010based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA: A Cancer J For Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20230403-00145","article-title":"Survival analysis of Malignant tumors in cancer registration areas of Hubei province in China, 2013 to 2015","volume":"45","author":"Yao","year":"2023","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.breast.2025.104609","article-title":"Ensuring access to multidisciplinary care in advanced breast cancer: a global expert review and call-to-action for 2025\u20132035 (Goal 4)","volume":"84","author":"Paluch-Shimon","year":"2025","journal-title":"Breast"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2500168","DOI":"10.1200\/go-25-00168","article-title":"Establishing requirements for breast centers in low- and middle-income countries: a South African perspective","volume":"11","author":"Nietz","year":"2025","journal-title":"JCO Global Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06687-w","article-title":"The status of nuclear medicine in China: the first official national survey","volume":"51","author":"Zhang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.remnie.2025.500139","article-title":"PET\/CT in breast cancer","volume":"44","author":"Bastidas","year":"2025","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e250019","DOI":"10.1148\/rycan.250019","article-title":"Global cancer imaging access: Addressing barriers and harnessing innovations","volume":"7","author":"Hussain","year":"2025","journal-title":"Radiology: Imaging Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12885-024-13336-w","article-title":"Epidemiology of breast cancer in Chinese women from 1990 to 2021: a systematic analysis and comparison with the global burden","volume":"25","author":"Long","year":"2025","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102797","DOI":"10.1016\/j.canep.2025.102797","article-title":"Breast cancer characteristics in low- and middle-income countries: An umbrella review","volume":"96","author":"Tolentino-Rodriguez","year":"2025","journal-title":"Cancer Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a lancet oncology commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e077089","DOI":"10.1136\/bmjopen-2023-077089","article-title":"Access to innovative anticancer medicines in China: a national survey on availability, price and affordability","volume":"14","author":"Li","year":"2024","journal-title":"BMJ Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1186\/s12889-025-23570-x","article-title":"A survey of availability, price, and affordability of innovative negotiated anticancer medicines: a retrospective study in Jiangsu Province, eastern China","volume":"25","author":"Ma","year":"2025","journal-title":"BMC Public Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1729325","article-title":"Availability, price and affordability of anticancer medicines in Jiangsu Province, China: a cross-sectional survey study","volume":"13","author":"Yao","year":"2025","journal-title":"Front Public Health"},{"key":"B23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/healthcare13060686","article-title":"Intended and unintended impacts of \u20184+7\u2019 volume-based drug procurement on the use of drugs in China: a natural experimental study","volume":"13","author":"Zhao","year":"2025","journal-title":"Healthcare"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1186\/s12913-025-13575-y","article-title":"Impact of six rounds of national drug price negotiation on availability, cost, use, and prices of targeted drugs in China","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/go-25-00457","article-title":"Cyclin-dependent kinase 4\/6 inhibitor in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: global challenges and Tibremciclib perspective","volume":"11","author":"Khalid","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1530391","article-title":"Real-world effectiveness of CDK4\/6i in first-line treatment of HR+\/HER2- advanced\/metastatic breast cancer: updated systematic review","volume":"15","author":"Harbeck","year":"2025","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"104417","DOI":"10.1016\/j.breast.2025.104417","article-title":"Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: a prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems","volume":"80","author":"Antonini","year":"2025","journal-title":"Breast"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1200\/jco.2022.40.16_suppl.1056","article-title":"CDK4\/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression","volume":"40","author":"Lapuchesky","year":"2022","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2024.06.020","article-title":"Opioid access among advanced cancer patients in low- and middle-income countries in Asia","volume":"68","author":"Andres","year":"2024","journal-title":"J Pain Symptom Manage"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32513-8","article-title":"Alleviating the access abyss in palliative care and pain relief\u2014an imperative of universal health coverage: the Lancet Commission report","volume":"391","author":"Knaul","year":"2018","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/2224-3151.239416","article-title":"Access to pain relief and essential opioids in the WHO South-East Asia Region: challenges in implementing drug reforms","volume":"7","author":"Vallath","year":"2018","journal-title":"WHO South East Asia J Public Health"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2024.10.026","article-title":"Distributed opioids in morphine equivalent: a global measure of availability for palliative care","volume":"69","author":"Knaul","year":"2025","journal-title":"J Pain Symptom Manage"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5032","article-title":"Advancing global pharmacoequity in oncology","volume":"11","author":"Erfani","year":"2025","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0297340","DOI":"10.1371\/journal.pone.0297340","article-title":"County medical community, medical insurance package payment, and hierarchical diagnosis and treatment\u2014empirical analysis of the impact of the pilot project of compact county medical communities in Sichuan Province","volume":"19","author":"Fort","year":"2024","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12913-019-4153-7","article-title":"Factors associated with the inter-facility transfer of inpatients in Sichuan province, China","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"S951","DOI":"10.1016\/j.annonc.2024.08.1632","article-title":"1570P factors and impacts of delayed presentation for county-level patients with breast cancer in a real-life setting in China","volume":"35","author":"Ji","year":"2024","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.clon.2022.05.007","article-title":"Presentation, diagnosis and treatment delays in breast cancer care and their associations in Sri Lanka, a low-resourced country","volume":"34","author":"Hewage","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.s453857","article-title":"Factors influencing breast cancer awareness in rural southwest China: a cross-sectional study","volume":"16","author":"Zhu","year":"2024","journal-title":"Int J Women's Health"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.842837","article-title":"The urban-rural disparities and associated factors of health care utilization among cancer patients in China","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad347","article-title":"Rural-urban disparities in colorectal cancer screening, diagnosis, treatment, and survivorship care: a systematic review and meta-analysis","volume":"29","author":"Sepassi","year":"2024","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1186\/s12885-024-13267-6","article-title":"Assessing the continuum of care in Sub-Saharan African hospitals performing surgery for breast cancer: a secondary analysis of the GlobalSurg 3 study","volume":"24","author":"Gnangnon","year":"2024","journal-title":"BMC Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.radmp.2024.05.006","article-title":"Assessment of radiotherapy and diagnosis resources allocation in Shanghai, China","volume":"5","author":"Yang","year":"2024","journal-title":"Radiat Med Prot"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17152-9","article-title":"Disparities in refusal of adjuvant radiation for breast-conserving therapy in the USA","volume":"32","author":"Bhadouriya","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2100358","DOI":"10.1200\/go.21.00358","article-title":"Access to radiation therapy: From local to global and equality to equity","volume":"8","author":"Laskar","year":"2022","journal-title":"JCO Global Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2023.11.012","article-title":"Favorable breast cancer mortality-to-incidence ratios of countries with good human development index rankings and high health expenditures","volume":"63","author":"Chou","year":"2024","journal-title":"Taiwanese J Obstetrics Gynecology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"103714","DOI":"10.1016\/j.breast.2024.103714","article-title":"Factors influencing the time to diagnosis and treatment of breast cancer among women in low- and middle-income countries: a systematic review","volume":"75","author":"Subedi","year":"2024","journal-title":"Breast"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1186\/s12913-022-08927-x","article-title":"Health system barriers influencing timely breast cancer diagnosis and treatment among women in low and middle-income Asian countries: evidence from a mixed-methods systematic review","volume":"22","author":"Afaya","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1186\/s12909-025-07540-w","article-title":"Application of multidisciplinary diagnosis and treatment (MDT) clinical teaching model in the clinical teaching of some undergraduates of breast diseases in surgery","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Med Educ"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101294","DOI":"10.1016\/j.lanepe.2025.101294","article-title":"Strengthening health technology assessment for cancer treatments in Europe by integrating causal inference and target trial emulation","volume":"52","author":"Bucher","year":"2025","journal-title":"Lancet Regional Health - Europe"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7326\/annals-24-00614","article-title":"Time from approval to reimbursement of new drugs: a comparative analysis between the United States, England, Germany, France, and Switzerland (2011-2022)","volume":"177","author":"Glaus","year":"2024","journal-title":"Ann Intern Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:47:43Z","timestamp":1779252463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1847827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":50,"alternative-id":["10.3389\/fonc.2026.1847827"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1847827","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"article-number":"1847827"}}